Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Mallinckrodt plc

Get SEC filing alerts via email and in your feed for Mallinckrodt plc

MCKPF

Mallinckrodt plc

About Mallinckrodt plc

Mallinckrodt plc is a global specialty pharmaceutical company focused on developing, manufacturing, and marketing branded and generic products for underserved patients with severe conditions. Its core segments include Specialty Brands, offering innovative therapies for autoimmune and rare diseases, and Specialty Generics, producing controlled substances and APIs. The company emphasizes innovation, regulatory compliance, and strategic transactions to expand its portfolio and market presence.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Mallinckrodt plc

1
1
Mallinckrodt plc Keenova Therapeutics Reports 126% Revenue Growth to $468.3 Million in Q1 2026

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
Mallinckrodt plc Keenova Therapeutics Reports $1.43 Billion in Net Sales, Faces $457.5 Million Loss

Via official filing (AI summary) | about 2 months ago | 0 comments

3
1
Mallinckrodt plc Mallinckrodt Reports 49% Revenue Increase to $753.1 Million Amid Business Combination with Endo

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Mallinckrodt plc Mallinckrodt Reports Decline in Q2 2025 Sales, Despite Increased Gross Profit

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Mallinckrodt plc Mallinckrodt Reports $27.7 Million Net Loss, Sees Improvement in Gross Profit

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Mallinckrodt plc Mallinckrodt Reports $1.98 Billion in Net Sales for Fiscal Year 2024, Driven by Specialty Generics Growth

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Mallinckrodt plc Mallinckrodt Reports Improved Revenue and Profitability in Q3 2024, Net Loss Narrows

Via official filing (AI summary) | over 1 year ago | 0 comments